Dramatic regression of recalcitrant human papillomavirus type 1-related palmar verrucae and squamous cell carcinomain situfollowing R-CHOP chemotherapy and transition to sirolimus in a renal transplant patient with diffuse large B cell lymphoma

2014 ◽  
Vol 54 (5) ◽  
pp. e119-e121 ◽  
Author(s):  
Karl K. Vance ◽  
Aleksandar L. Krunic ◽  
Patricia M. Fishman ◽  
Shrihari S. Kadkol ◽  
Gerard J. Nuovo
Keyword(s):  
Human Papillomavirus ◽  
Renal Transplant ◽  
Renal Transplant Patient ◽  
Transplant Patient ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Chop Chemotherapy ◽  
Large B Cell Lymphoma ◽  
Large B Cell

scholarly journals Detection of the Incidence of HBV, HCV Infection and Febrile Neutropenia Associated With CHOP With or Without Rituximab in Diffuse Large B-Cell Lymphoma–Treated Patients

2017 ◽  
Vol 53 (3) ◽  
pp. 194-197 ◽  
Author(s):  
Kashif Ali ◽  
Ali Akbar Sial ◽  
Mirza Tasawer Baig ◽  
Nida Baig ◽  
Saqib Hussain Ansari ◽  
...  
Keyword(s):  
Hepatitis B ◽  
Febrile Neutropenia ◽  
B Cell ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Hcv Infection ◽  
Patient Records ◽  
Chop Chemotherapy ◽  
Large B Cell Lymphoma ◽  
Large B Cell

Background: Reactivation of hepatitis B virus (HBV) and hepatitis C virus (HCV) and febrile neutropenia (FN) are common in diffuse large B-cell lymphoma (DLBCL) patients undergoing cyclophosphamide, hydroxyrubicin, Oncovin, and prednisolone (CHOP) or cyclophosphamide, hydroxyrubicin, Oncovin, prednisolone - rituximab containing (R-CHOP) chemotherapy. This ultimately leads to delaying the therapy, increasing hospital stay, and raising the pharmacoeconomic burden on patients. Aim and Objective: The aim of this study was to determine the incidence of HBV and HCV infection and febrile neutropenia in DLBCL patients treated with R-CHOP and CHOP. Methodology: This was an institutional approved study in which patient records from a private hospital, specialized in hematology and oncology (Karachi, Pakistan), were reviewed retrospectively from 2014 to 2016. Patients aged above 18 years with known diagnosis of DLBCL who underwent CHOP-21 or R-CHOP-21 chemotherapy regimen were included. Baseline blood chemistry and liver function tests along with the data regarding HBV (hepatitis B surface antigen [HBsAg], hepatitis B surface antibody [anti-HBs]), HCV (antibody anti-HCV), and febrile neutropenia were collected from patient records. Results: In total, 35 cases of DLBCL were treated during a 3-year period (ie, from 2014 to 2016), of which 16 were on CHOP-21 regimen whereas 19 were treated with R-CHOP-21. Of the 19 patients who underwent R-CHOP chemotherapy, only 2 (10%) patients were HBsAg reactive. Before commencing the second cycle, 2 (10%) patients reported to hospital with fever and had hematological (low neutrophil count) and microbiological ( Escherichia coli) proven febrile neutropenia. The incidence of HBV infection post treatment was lower in group treated with CHOP (1 patient showed HBsAg reactivity).

scholarly journals Interaction between BCL2 and Interleukin-10 Gene Polymorphisms Alter Outcomes of Diffuse Large B-Cell Lymphoma following Rituximab Plus CHOP Chemotherapy

2009 ◽  
Vol 15 (6) ◽  
pp. 2107-2115 ◽  
Author(s):  
Yeon Hee Park ◽  
Sang Kyun Sohn ◽  
Jong Gwang Kim ◽  
Myung-Hoon Lee ◽  
Hong Suk Song ◽  
...  
Keyword(s):  
B Cell ◽  
Gene Polymorphisms ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Interleukin 10 ◽  
Chop Chemotherapy ◽  
Large B Cell Lymphoma ◽  
Large B Cell

scholarly journals A multi-institutional and case-matched control study on treatment outcomes of consolidative radiotherapy after a full course of R-CHOP compared with R-CHOP alone in Stage I–II diffuse large B-cell lymphoma (KROG 17-02)

2019 ◽  
Vol 60 (5) ◽  
pp. 677-684
Author(s):  
Mi Joo Chung ◽  
Won Kyung Cho ◽  
Dongryul Oh ◽  
Keun-Yong Eom ◽  
Jin Hee Kim ◽  
...  
Keyword(s):  
B Cell ◽  
Treatment Outcomes ◽  
Tumor Size ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Stage I ◽  
Chop Chemotherapy ◽  
Bulky Disease ◽  
Large B Cell Lymphoma ◽  
Large B Cell

Abstract We compared treatment outcomes between rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) chemotherapy alone with R-CHOP followed by consolidative radiation therapy (RT) in diffuse large B-cell lymphoma (DLBCL). We analyzed 404 patients with Stage I–II DLBCL who received six to eight cycles of R-CHOP and achieved a good response after a full course of chemotherapy. Propensity-score matching was used to assess the role of consolidative RT. The R-CHOP alone group (n = 184) was matched in a 1:2 ratio with the R-CHOP plus RT group (n = 92). Twenty-four (13.0%) of 184 patients receiving R-CHOP alone and 8 (8.7%) of 92 patients receiving R-CHOP plus RT had bulky diseases (>7.5 cm). A Deauville score of 1–2 was achieved for 159 (86.4%) of 184 patients receiving R-CHOP alone and 84 (91.3%) of 92 patients receiving R-CHOP plus RT. After a median follow-up time of 42 months, the recurrence-free survival (RFS) rate (86.7% vs 93.0%, P = 0.464) and overall survival rate (88.3% vs 95.1%, P = 0.295) at 5 years did not differ significantly between the R-CHOP alone and R-CHOP plus RT arms. In the additional multivariate analyses, large tumor size (>7.5 cm) was significantly associated with decreased RFS (hazard ratio, 2.368 and confidence interval, 1.837–6.697; P = 0.048). Consolidative radiation was not a significant factor for RFS (P = 0.563). Tumor size was a significant factor for RFS in the rituximab era. The outcome of omitting consolidative RT for good responders after six to eight cycles of R-CHOP chemotherapy was acceptable in early-stage DLBCL without a bulky disease.

Addition of Rituximab to CHOP Chemotherapy Does Not Improve Clinical Outcome in Patients with Localized Gastric Diffuse Large B-Cell Lymphoma: A Retrospective Study by Ganken Adult Lymphoma Study Group (Single Institute Analysis).

Blood ◽  
2007 ◽  
Vol 110 (11) ◽  
pp. 4449-4449
Author(s):  
Masahiro Yokoyama ◽  
Daisuke Ennishi ◽  
Hiroaki Asai ◽  
Kyoko Ueda ◽  
Makoto Kodaira ◽  
...  
Keyword(s):  
Radiation Therapy ◽  
Clinical Outcome ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Chop Chemotherapy ◽  
Chop Regimen ◽  
Free Survival ◽  
Large B Cell Lymphoma ◽  
Improve Clinical Outcome ◽  
Large B Cell

Abstract Background: In recent years, it has been reported that addition of rituximab to CHOP chemotherapy significantly improves event-free survival (EFS) and overall survival (OS) compared with standard CHOP alone in patients with diffuse large B-cell lymphoma (DLBCL). On the other hand, gastric DLBCL is a good clinical outcome without surgical excision in the group of primary extranodal DLBCL. Localized gastric DLBCL shows very good EFS and OS treated with standard CHOP plus radiation therapy without rituximab. Methods: We analyzed retrospectively the prognosis between R-CHOP and CHOP alone in patients with localized gastric DLBCL. All 24 patients diagnosed between July 1999 and July 2006 in our hospital, were included in this study. The pathology was reviewed by a hematopathologist and confirmed to be de novo DLBCL according to the WHO classification. The staging system was using by Lugano meeting classification. Patients with stage IIE and IV were excluded. All patients were initially treated with six cycles of CHOP or R-CHOP regimen consisting of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone. If we evaluated partial response after six cycles of chemothrapy, the patients have been added radiation therapy. Results: Initial characteristics of the 24 patients are summarized in Table 1. The median age of patients at time of inclusion was 67.5 yr (range 30–83 yr). The median follow up of surviving patients was 30 months. CR rates between CHOP and R-CHOP were 91.7% vs. 83.3%, p=1.000, and overall response rates were 100% vs. 83.3%, p=.478, respectively. 2 years progression-free survival and overall survival were no statistical significance difference between two groups (Log rank test: P=.138, P=.739). Conclusion: These results suggested that addition of rituximab to CHOP chemotherapy does not improve clinical outcome of localized gastric DLBCL. The patients with localized gastric DLBCL did not get the clinical benefits of rituximab. As you know, rituximab needs high costs, so we recommend standard CHOP regimen plus radiation therapy in patients with localized gastric DLBCL, without rituximab combination regimen. Characteristics of the 24 patients with localized gastric DLBCL Characteristic CHOP (n=12) R-CHOP (n=12) P Age 1.000 =<60 3 4 >60 9 8 Male 7 6 1.000 Stage (Lugano) .890 I 4 3 II 1 7 9 Unknown 1 0 IPI score .867 0,1 7 7 2 4 5 Unknown 1 0

Sign in / Sign up

Export Citation Format

Share Document